Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|ANBL09P1||COG||A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma: A Limited Institution Pilot Study||Pediatric CIRB||Available to Open|
|S1403||SWOG||A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced; EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) (BI 1200.124)||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-HN003||NRG||A Phase I and Expansion Cohort Study of Adjuvant Cisplatin; Intensity-Modulated Radiotherapy; and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)||Adult CIRB - Early Phase Emphasis||Available to Open|
|9608||ETCTN||A Phase I Trial of ABT-263 (Navitoclax); a Bcl-2 inhibitor; and Sorafenib (Nexavar) in Patients with Relapsed or Refractory Solid Organ Tumors||Adult CIRB - Early Phase Emphasis||Available to Open|
|ALTE11C1||COG||Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma: A Groupwide Non-Therapeutic Protocol||Pediatric CIRB||Available to Open|
|10057||ETCTN||A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors||Adult CIRB - Early Phase Emphasis||Available to Open|
|WF-20817CD||NCORP-Wake Forest University||Implementation of Smoking Cessation Services Within NCI NCORP Community Sites with Organized Lung Cancer Screening Programs||Cancer Prevention and Control CIRB||Available to Open|
|AALL1621||COG||A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518; IND#TBD) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)||Pediatric CIRB||Available to Open|
|NRG-GY018||NRG||A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|A031702||Alliance||Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors||Adult CIRB - Late Phase Emphasis||Available to Open|